Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Up 3,400.0% in February

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 17,500 shares, a growth of 3,400.0% from the February 13th total of 500 shares. Based on an average daily trading volume, of 318,700 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the company’s stock are sold short.

Provectus Biopharmaceuticals Stock Up 5.5 %

Shares of Provectus Biopharmaceuticals stock traded up $0.01 on Wednesday, hitting $0.11. The company had a trading volume of 449,379 shares, compared to its average volume of 193,219. The stock has a 50-day moving average of $0.11 and a 200-day moving average of $0.11. Provectus Biopharmaceuticals has a twelve month low of $0.04 and a twelve month high of $0.22.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.